LoQus23 Therapeutics

Cambridge, United Kingdom · Founded 2019 · Privately Held (backing)

Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. LoQus23 Therapeutics is based in Cambridge, United Kingdom and was founded in 2019. Its last known valuation is $61.4 million. It has raised $67.2 million.

Last price · $/share

—

Implied valuation

$61.4M

Total raised

$67.2M

Last round

—

How much has LoQus23 Therapeutics raised?

$67.2Macross 0 recorded rounds

Free account

More of LoQus23 Therapeutics with a free account

·Watch LoQus23 Therapeutics: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

LoQus23 Therapeutics investors

3 investors are on record for LoQus23 Therapeutics, including SV Health Investors, Forbion and Novartis Venture Fund.

For fundraisers

Raising for a company like LoQus23 Therapeutics?

3 investors have backed LoQus23 Therapeutics.

See all 3 investors →

Frequently asked about LoQus23 Therapeutics

How much has LoQus23 Therapeutics raised?: LoQus23 Therapeutics has raised $67.2M in total across 0 recorded funding rounds.